PL3443987T3 - Kompozycja farmaceutyczna do zapobiegania otyłości wywołanej dietą - Google Patents
Kompozycja farmaceutyczna do zapobiegania otyłości wywołanej dietąInfo
- Publication number
- PL3443987T3 PL3443987T3 PL18188634T PL18188634T PL3443987T3 PL 3443987 T3 PL3443987 T3 PL 3443987T3 PL 18188634 T PL18188634 T PL 18188634T PL 18188634 T PL18188634 T PL 18188634T PL 3443987 T3 PL3443987 T3 PL 3443987T3
- Authority
- PL
- Poland
- Prior art keywords
- diet
- prevention
- pharmaceutical composition
- induced obesity
- obesity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721029447 | 2017-08-19 | ||
| EP18188634.2A EP3443987B1 (en) | 2017-08-19 | 2018-08-13 | A pharmaceutical composition for prevention of diet induced obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3443987T3 true PL3443987T3 (pl) | 2021-08-02 |
Family
ID=63244444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18188634T PL3443987T3 (pl) | 2017-08-19 | 2018-08-13 | Kompozycja farmaceutyczna do zapobiegania otyłości wywołanej dietą |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10702487B2 (pl) |
| EP (1) | EP3443987B1 (pl) |
| CA (1) | CA3012675C (pl) |
| CY (1) | CY1124010T1 (pl) |
| DK (1) | DK3443987T3 (pl) |
| EA (1) | EA201891651A3 (pl) |
| ES (1) | ES2864136T3 (pl) |
| HR (1) | HRP20210466T1 (pl) |
| HU (1) | HUE053678T2 (pl) |
| LT (1) | LT3443987T (pl) |
| MY (1) | MY177974A (pl) |
| PH (1) | PH12018000207A1 (pl) |
| PL (1) | PL3443987T3 (pl) |
| PT (1) | PT3443987T (pl) |
| RS (1) | RS61628B1 (pl) |
| SG (1) | SG10201806472SA (pl) |
| SI (1) | SI3443987T1 (pl) |
| SM (1) | SMT202100168T1 (pl) |
| UA (1) | UA122710C2 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170305898A1 (en) | 2016-04-20 | 2017-10-26 | Veroscience Llc | Composition and Method for Treating Metabolic Disorders |
| WO2021041495A2 (en) * | 2019-08-26 | 2021-03-04 | The Trustees Of Indiana University | Method to maintain or enhance tissue |
| CA3149877A1 (en) | 2019-09-23 | 2021-04-01 | Anthony H. Cincotta | Method for inducing tumor regression |
| CN111084301B (zh) * | 2019-12-30 | 2023-08-22 | 内江师范学院 | 一种桑叶提取物鱼饲料粘合剂及制备方法和应用 |
| CN113712206A (zh) * | 2021-09-16 | 2021-11-30 | 湖南希尔天然药业有限公司 | 一种含有桑叶dnj和桑叶肽的组合物及其制备方法 |
| KR20240134319A (ko) * | 2021-12-13 | 2024-09-09 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 올레오일에탄올아마이드의 생체 이용 가능한 제형을 이용한 간지방증 치료 방법 |
| US20250375406A1 (en) * | 2022-06-24 | 2025-12-11 | Veroscience Llc | Treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
| CN119591575B (zh) * | 2024-08-19 | 2025-09-30 | 河北农业大学 | 一种大豆苷元药物共晶体及其制备方法和应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4042687A (en) * | 1975-11-24 | 1977-08-16 | Control Drug, Inc. | Method of treating obesity by the oral administration of a predigested protein composition |
| MXPA03008823A (es) | 2001-03-27 | 2004-08-12 | Univ California | Metodos, compuestos y composiciones para reducir la grasa corporal y modular el metabolismo de los acidos grasos. |
| US20050054730A1 (en) * | 2001-03-27 | 2005-03-10 | The Regents Of The University Of California | Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha |
| US20050101542A1 (en) | 2002-08-20 | 2005-05-12 | Regents Of The University Of California | Combination therapy for controlling appetites |
| AU2003290387A1 (en) | 2002-11-18 | 2004-06-15 | Natural Asa | Dietry supplements and foods product comprising oleylethanolamide |
| WO2004078113A2 (en) | 2003-03-04 | 2004-09-16 | Pharmacia Corporation | Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents |
| CA2542547A1 (en) | 2003-10-16 | 2005-05-26 | Daniele Piomelli | Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism |
| US20090054526A1 (en) | 2005-07-14 | 2009-02-26 | Hansen Harald S | Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders |
| JP5388602B2 (ja) * | 2008-01-25 | 2014-01-15 | 小林製薬株式会社 | 抗肥満用医薬組成物 |
| AU2009249582B2 (en) | 2008-05-19 | 2014-07-31 | Nestec S.A. | Methods for reducing lipid absorption by an animal |
| CA2843265C (en) | 2010-07-28 | 2019-09-17 | The Regents Of The University Of California | Peripherally restricted faah inhibitors |
| WO2012090225A2 (en) | 2010-12-29 | 2012-07-05 | Nutracryst Therapeutics Private Limited | Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent |
| CA2835429A1 (en) | 2011-05-10 | 2012-11-15 | Nestec S.A. | Methods and compositions for promoting lean body mass growth |
| EP2744778B1 (en) | 2011-08-19 | 2019-01-16 | The Regents of The University of California | Meta-substituted biphenyl peripherally restricted faah inhibitors |
| CN102579414A (zh) | 2012-01-29 | 2012-07-18 | 厦门大学 | 油酰乙醇胺作为降血脂、防治非酒精性脂肪肝药物的用途 |
| RU2685425C2 (ru) | 2012-07-24 | 2019-04-18 | Биал-Портела Энд Ка, С.А. | Соединения мочевины и их применение в качестве ингибиторов ферментов |
| EP2892366A1 (en) | 2012-09-07 | 2015-07-15 | Nestec S.A. | Oleoylethanolamide compositions |
| ITMI20131180A1 (it) | 2013-07-15 | 2015-01-16 | Fond Istituto Italiano Di Tecnologia | O-alchil triazolil carbammati come inibitori di idrolasi delle ammidi degli acidi grassi (faah) |
| US9828352B2 (en) | 2013-07-18 | 2017-11-28 | Fondazione Istituto Italiano Di Tecnologia | Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR) |
| SI3024825T1 (sl) | 2013-07-24 | 2017-11-30 | Bial - Portela & Ca, S.A. | Imidazolkarboksamidi in njihova uporaba kot faah inhibitorji |
| MX2016001391A (es) | 2013-08-01 | 2016-08-17 | BIAL - PORTELA & Cª S A | Compuestos de urea y su uso como inhibidores de la enzima amida hidrolasa de acido graso (faah). |
| WO2015157313A1 (en) | 2014-04-07 | 2015-10-15 | The Regents Of The University Of California | Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments |
| MA42130A (fr) | 2015-05-21 | 2018-03-28 | Therapix Biosciences Ltd | Combinaisons d'opioïdes et de n-acyléthanolamines |
| CN116999410A (zh) | 2015-08-11 | 2023-11-07 | Eyesiu医疗股份有限公司 | 具有生物活性亲脂性化合物的聚乙二醇化脂质纳米粒 |
-
2018
- 2018-07-26 US US16/046,482 patent/US10702487B2/en active Active
- 2018-07-27 CA CA3012675A patent/CA3012675C/en active Active
- 2018-07-27 MY MYPI2018702652A patent/MY177974A/en unknown
- 2018-07-30 SG SG10201806472SA patent/SG10201806472SA/en unknown
- 2018-07-31 PH PH12018000207A patent/PH12018000207A1/en unknown
- 2018-08-13 PL PL18188634T patent/PL3443987T3/pl unknown
- 2018-08-13 PT PT181886342T patent/PT3443987T/pt unknown
- 2018-08-13 SI SI201830245T patent/SI3443987T1/sl unknown
- 2018-08-13 RS RS20210359A patent/RS61628B1/sr unknown
- 2018-08-13 DK DK18188634.2T patent/DK3443987T3/da active
- 2018-08-13 ES ES18188634T patent/ES2864136T3/es active Active
- 2018-08-13 HU HUE18188634A patent/HUE053678T2/hu unknown
- 2018-08-13 EP EP18188634.2A patent/EP3443987B1/en active Active
- 2018-08-13 LT LTEP18188634.2T patent/LT3443987T/lt unknown
- 2018-08-13 SM SM20210168T patent/SMT202100168T1/it unknown
- 2018-08-16 UA UAA201808780A patent/UA122710C2/uk unknown
- 2018-08-16 EA EA201891651A patent/EA201891651A3/ru unknown
-
2021
- 2021-03-19 HR HRP20210466TT patent/HRP20210466T1/hr unknown
- 2021-03-23 CY CY20211100251T patent/CY1124010T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA122710C2 (uk) | 2020-12-28 |
| CA3012675C (en) | 2021-06-15 |
| SI3443987T1 (sl) | 2021-07-30 |
| EA201891651A3 (ru) | 2019-05-31 |
| PH12018000207B1 (en) | 2019-06-03 |
| EP3443987A1 (en) | 2019-02-20 |
| PT3443987T (pt) | 2021-03-18 |
| PH12018000207A1 (en) | 2019-06-03 |
| DK3443987T3 (da) | 2021-03-22 |
| SG10201806472SA (en) | 2019-03-28 |
| US10702487B2 (en) | 2020-07-07 |
| CA3012675A1 (en) | 2019-02-19 |
| HRP20210466T1 (hr) | 2021-05-14 |
| CY1124010T1 (el) | 2022-05-27 |
| MY177974A (en) | 2020-09-28 |
| RS61628B1 (sr) | 2021-04-29 |
| SMT202100168T1 (it) | 2021-05-07 |
| US20190054046A1 (en) | 2019-02-21 |
| ES2864136T3 (es) | 2021-10-13 |
| EA201891651A2 (ru) | 2019-02-28 |
| BR102018016746A8 (pt) | 2023-02-14 |
| LT3443987T (lt) | 2021-04-26 |
| BR102018016746A2 (pt) | 2019-03-26 |
| EP3443987B1 (en) | 2020-12-23 |
| HUE053678T2 (hu) | 2021-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3565550T (pt) | Composições farmacêuticas compreendendo meloxicam e rizatriptano | |
| IL258402A (en) | Electroporation for obesity or diabetes treatment | |
| ZA201906613B (en) | Pharmaceutical compositions for combination therapy | |
| HUE070065T2 (hu) | Gyógyszerkészítmények, amelyek meloxikámot tartalmaznak | |
| PL3443987T3 (pl) | Kompozycja farmaceutyczna do zapobiegania otyłości wywołanej dietą | |
| DK3256138T3 (da) | Farmaceutiske sammensætninger omfattende meloxicam | |
| DK3529248T3 (da) | Farmaceutiske sammensætninger | |
| DK3655017T3 (da) | Farmaceutisk sammensætning | |
| DK3253382T3 (da) | Farmaceutiske sammensætninger til kombinationsterapi | |
| DK3102213T3 (da) | Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser | |
| HUE055263T2 (hu) | 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére | |
| ZA201905510B (en) | Pharmaceutical compositions for combination therapy | |
| IL253854B (en) | Mebendazole polymorph for treatment and prevention of tumors | |
| PL3573620T3 (pl) | Kompozycje do leczenia nadciśnienia | |
| DK3583943T3 (da) | Farmaceutisk sammensætning | |
| DK3203999T3 (da) | Substituerede aromatiske forbindelser og farmaceutiske sammensætninger til forebyggelse og behandling af osteoporose | |
| DK3728220T3 (da) | Farmaceutiske forbindelser | |
| SMT202400478T1 (it) | Composizione farmaceutica | |
| DK3288933T3 (da) | Oxindolforbindelser og farmaceutiske sammensætninger deraf | |
| DK3203998T3 (da) | Substituerede aromatiske forbindelser og farmaceutiske sammensætninger til forebyggelse og behandling af diabetes | |
| HUE047272T2 (hu) | Gyógyászati kompozíció rák kezelésére és/vagy megelõzésére | |
| DK3250218T3 (da) | Naktidpeptid til behandling af fedme | |
| EP3579855A4 (en) | ANTI-PATHOGENIC THERAPEUTIC COMPOSITIONS | |
| DK3548006T3 (da) | Sammensætning til behandling af tarmforandringer | |
| EP3253379A4 (en) | Pharmaceutical composition for the treatment of obesity |